M&A Deal Summary |
|
|---|---|
| Date | 2021-07-26 |
| Target | InSilico Solutions |
| Sector | Medical Products |
| Buyer(s) | Kiromic |
| Deal Type | Add-on Acquisition |
SEARCH BY
Kiromic is an immuno-oncology, target discovery, and gene editing company developing highly effective and safe tumor-specific cancer engineered immunotherapies to face and defeat multiple cancer types. The company focused on extending the benefits of immunotherapy by leveraging Diamond AI (Kiromic Diamond Artificial Intelligence), which is a multi-purpose computational platform that can identify new cancer immunological targets for T-Cells and B-Cells. Kiromic was founded in 2006 and is based in Houston, Texas.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Medical Products M&A | 1 of 1 |
| Type: Add-on Acquisition M&A Deals | 1 of 1 |
| State: Virginia M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2021 M&A | 1 of 1 |